Association of biofilm production in ESBL and MBL producing clinical isolates of *Pseudomonas aeruginosa*

Kulkarni D.M¹, Nilekar S.L.², Vidhya T.³

¹Dr. Kulkarni D.M., Associate Professor, ²Dr. Nilekar S.L., Professor and HOD, ³Dr. Vidhya T., Resident; all authors are affiliated with the Department of Microbiology, S.R.T.R Government Medical College, Ambajogai, Maharashtra, India

**Corresponding Author:** Dr. Vidhya T., Department of Microbiology, S.R.T.R Government Medical College, Maharashtra, Beed, Ambajogai, Maharashtra, India. E-mail: vidhya220892@gmail.com, kulkarnibandapurkar@gmail.com

**Abstract**

**Introduction:** *Pseudomonas aeruginosa* is one of the most prevalent nosocomial pathogens that cause a life-threatening infection. One of the important characteristics of *P. aeruginosa* is biofilm formation and the most studied bacterium related to biofilm formation so far. The biofilm formation and beta-lactamases production synergistically contribute to the extensive dissemination of multi-drug resistant strains. **Aim:** The present study was conducted to identify biofilm-producing isolates of *P. aeruginosa* along with their antibiotic resistance pattern and ESBL and MBL production and to analyze their antibiogram. **Materials and methods:** Various clinical specimens were collected and totally 82 clinical isolates of *P. aeruginosa* were included in this study. Biofilm producing isolates were identified by the tube adherence method. **Results:** Among the total, 22 [26.83%] isolates were biofilm producers and the maximum number was obtained from blood [100%], followed by ETT [75%], and Drain [66.67%]. Biofilm producing isolates were showing more resistance in comparison to non-biofilm producers. All isolates of *P. aeruginosa* were sensitive to colistin and polymyxin B. Association of ESBL production and biofilm formation found to be statistically significant [p < 0.002], which was a contrast to association of MBL production and biofilm formation. **Conclusion:** High-level resistance to antimicrobial agents is a characteristic feature of infection caused by biofilm and lead to chronic infections. Knowledge about these biofilm-producing isolates is important in the clinical setting to eradicate these chronic and life-threatening infections.

**Keywords:** Antibiogram, Biofilm, ESBL, MBL, *Pseudomonas aeruginosa*,

**Introduction**

*Pseudomonas aeruginosa* is remarkably considered one of the most adaptive nosocomial pathogens [1]. Infections resulting from *P. aeruginosa* are frequently life-threatening and hard to treat causing elevated stay in a medical institution or even accelerated morbidity and mortality as it exhibits intrinsically excessive resistance to many antimicrobials and the development of multi-drug resistance in health care settings [2]. *Pseudomonas aeruginosa* is a gram-negative, non-fermenting, obligately aerobic, the saprophytic bacterium which is widely distributed [3]. It is known for its intrinsic resistance to several antimicrobials, disinfectants, and tolerance to a wide range of physical conditions [4]. One of the important characteristics of *P. aeruginosa* is biofilm formation [1] and the most studied bacterium related to biofilm formation so far [5]. At present, biofilm is a serious worldwide concern due to its extracellular polymeric substances (EPS) which plays a vital role in antimicrobial resistance [6,7]. The biofilm-producing bacteria may show higher Minimal Bactericidal Concentration (MBC) and Minimal Inhibitory Concentration (MIC) of antibiotics up to 100–1000 fold than the planktonic form of bacteria [8].

Biofilm forming bacteria cause chronic persistent infection [8] and life-threatening device-associated infection. The various medical devices are shown to be colonized by biofilm [9] which leads to device-associated nosocomial infection. This biofilm infection affects millions of people each year and many deaths occur as a consequence [10].

NIH publication showed more than 60% of all kinds of infections are related to the formation of biofilm [11]. In the present day, antibiotic resistance is an emerging problem and especially higher antibiotics like carbapenem are under the threat due to the widespread presence of carbapenemase (mainly Metallo Beta-lactamase). The biofilm formation and beta-lactamases (like ESBL and MBL) production synergistically contribute to the wide distribution of multi-drug resistant strains [12].
So the present study was conducted to identify, biofilm-producing isolates of *P. aeruginosa* along with their antibiotic resistance pattern and ESBL and MBL production. Also to find out the association between biofilm formation and drug resistance among *P. aeruginosa* in the hospital set up.

**Materials and methods**

**Place of study:** The study was carried in the Department of Microbiology at S.R.T.R Govt Medical College and Tertiary care center, Ambajogai, Maharashtra  
**Duration:** From December 2018 to November 2019.  
**Type of Study:** Observational study

**Sampling methods**- Specimens like Urine, Pus, Sputum, Drain, Blood, ETT (Endotracheal tube) were collected from patients admitted in various wards and ICUs. All specimens were cultured and identified by the standard conventional method [13]. Antimicrobial susceptibility testing (AST) was performed on Mueller-Hinton agar by Kirby Bauer's disc diffusion technique according to CLSI 2018 guidelines [14].

For ESBL and MBL detection- A Ceftazidime (CAZ 30µg) and Ceftazidime/clavulanic acid (CAZ/CA 30µg/10µg) disk were used to determine ESBL production. If there’s an increase of ≥ 5-mm in zone diameter for Ceftazidime, it is considered as ESBL producing isolates [14]. An imipenem (10 µg) and imipenem /EDTA (10 µg /750 µg) disk were used to determine MBL production. If there’s an increase of ≥ 7mm in zone diameter for imipenem – EDTA disc compared to zone diameter of imipenem disc, it was considered as MBL producing isolates [15].

**Detection of Biofilm formation by Tube Adherence method** - The isolated colony of *P. aeruginosa* was inoculated into a test tube contains trypticase soy broth (TSB) and incubated for 24 h at 35 °C. Next day content of the tube was discarded, and phosphate buffer saline was used to wash the tube and it was dried at room temperature. Then the tube was treated using 0.1% crystal violet for staining and then washed with water and dried. The presence of visible biofilm lining sidewall and the bottom of the tube was considered as biofilm producer [16].

**Sample size:** A total of 82 *P. aeruginosa* isolates identified were included in this study.

**Data analysis:** These study results were analyzed in SPSS version 16 software. Chai Square test was applied and *p*<0.05 was considered as significant.

**Ethical consideration and permission:** This study was reviewed and approved by the institutional ethical committee.

**Results**

A total of 82 isolates of *Pseudomonas aeruginosa* were recovered from various clinical specimens (Table 1).

**Table-1: Distribution of *Pseudomonas aeruginosa* from various clinical specimens**

| Specimens | No. (%) |
|-----------|---------|
| Urine     | 29 (35.37%) |
| Pus       | 23 (28.04%) |
| Sputum    | 21 (25.61%) |
| ETT       | 4 (4.88%)   |
| Drain     | 3 (3.66%)   |
| Blood     | 2 (2.44%)   |
| Total     | 82 (100%)   |

The rate of isolation of *Pseudomonas aeruginosa* from various clinical specimen has been shown in table 1. A maximum number of isolates were obtained from Urine 29 (35.37%), followed by Pus 23 (28.04%) and sputum 21 (25.61%).

All 82 isolates were tested for biofilm production by tube method as mentioned above. Among the total 22 (26.83%) isolates were biofilm producers and 60 (73.17%) were biofilm non-producers. Most of the biofilm-producing isolates were identified from ICU with 14 (63.64%), as compared to ward 8 (36.36%).
Among the total of 22 biofilm-producing, *P. aeruginosa* isolates, the maximum number was recovered from blood specimen (100%), followed by ETT (75%), and Drain (66.67%) all from invasive sites (Table-2).

### Table-2: Distribution of biofilm producer and non-biofilm producers in various clinical specimens

| Specimens | Biofilm producer | Non-Biofilm producer | Total |
|-----------|------------------|----------------------|-------|
|           | N (%)            | N (%)                |       |
| Urine     | 3 (10.34%)       | 26 (89.66%)          | 29 (100%) |
| Pus       | 7 (30.43%)       | 16 (69.57%)          | 23 (100%) |
| Sputum    | 5 (23.81%)       | 16 (76.19%)          | 21 (100%) |
| ETT       | 3 (75%)          | 1 (25%)              | 4 (100%) |
| Drain     | 2 (66.67%)       | 1 (33.33%)           | 3 (100%) |
| Blood     | 2 (100%)         | 0                    | 2 (100%) |
| **TOTAL** | **22 (26.83%)**  | **60 (73.17%)**      | **82 (100%)** |

Resistance to Ceftazidime (77% vs. 35%), Cefepime (77% vs.38%), Piperacillin-tazobactam (73% vs. 28%), Ciprofloxacin (68% vs. 22%), Gentamicin (59% vs. 27%), and Amikacin (32% vs. 8.3%) were higher among biofilm producing *P. aeruginosa* compared to non-biofilm producers (Statistically significant < 0.05) (Table 3).

### Table-3: Antibiotic Resistance pattern of *Pseudomonas aeruginosa* in relation to biofilm production

| Antibiotic                  | Biofilm          | P-Value |
|-----------------------------|------------------|---------|
|                             | Producer N (%) (n=22) | Non-Producer N (%) (n=60) | |
| Ceftazidime                 | 17 (77.27%)      | 21 (35%) | 0.000 |
| Cefepime                    | 17 (77.27%)      | 23 (38.33%) | 0.002 |
| Piperacillin-tazobactam     | 16 (72.72%)      | 17 (28.33%) | 0.000 |
| Gentamicin                  | 13 (59.09%)      | 16 (26.6%) | 0.009 |
| Ciprofloxacin               | 15 (68.18%)      | 13 (21.6%) | 0.000 |
| Meropenem                   | 3 (13.63%)       | 3 (5%) | 0.23 |
| Amikacin                    | 7 (31.8%)        | 5 (8.3%) | 0.015 |
| Colistin                    | 0                | 0 | * |
| Polymyxin B                 | 0                | 0 | * |

In the present study, biofilm-producing *Pseudomonas aeruginosa* showed high-level resistance i.e. 77%, 73%, 68%, 59% to an antipseudomonal cephalosporin (Ceftazidime and Cefepime), Piperacillin-tazobactam, Ciprofloxacin, Gentamicin, respectively. Somewhat lower resistance was observed to Amikacin (32%) and Meropenem (14%). All isolates of *P. aeruginosa* were sensitive to polymyxin B and colistin (Figure 1).
Among 82 *Pseudomonas aeruginosa* isolates, 32(39.02%) were ESBL producers. Among non-biofilm producers 28.33% and among biofilm producers 68.18% were ESBL producers. The maximum ESBL producer was biofilm positive with the statistically significant association (p-value =0.002). Totally in the present study 3(3.65%), isolates were MBL producers among all. Among non-biofilm producers 1.69% and among biofilm producers 9.09% were MBL producers. Although MBL production was comparatively higher in biofilm producers it was not statistically significant (P = 0.19).

### Discussion

*P. aeruginosa* causes the leading and life-threatening nosocomial infections, ranking only second among the gram-negative pathogens [4]. As per the CDC statement, the *P. aeruginosa* infection rate was near about 0.4% in the US hospitals and 4th common nosocomial pathogen accounts for 10.1% of all hospital-acquired infections [17]. The main problem in treating *P. aeruginosa* infection is its high-level resistance to various antibiotics. Studies show that infection by drug-resistant *P. aeruginosa* leads to increased length of hospital stay, morbidity, and mortality, and chronic infection [18]. The biofilm formation along with beta-lactamase production further complicates the scenario [12]. Production of an extracellular matrix is the hallmarks of a mature biofilm that acts as a barrier for any antibiotics and increases resistance to these antibiotics [19].

In the present study, among a total of 82 isolates of *P. aeruginosa*, 22(26.3%) were biofilm-producer and this finding is comparable with other studies which show (27.05%) [20], (32.3%) [21] and (33%) [22], but in contrast with others who showed higher rate of biofilm production (73.68%) [12] and (83.33%) [23]. This variation in the rate of isolation also may be due to sample size, type of specimen studied because medical devices were frequently colonized by biofilm-forming organisms and the various methods used for biofilm identification like Congo red agar method or Tissue culture plate which were showing a higher rate of detection.

The present study show, maximum biofilm-producing isolates recovered from specimens received from ICU (63.64%) compared to the ward (36.36%) and similar findings was shown in another study (83.3%)[2]. This could be possibly due to the ICU setup uses multiple medical devices for treatment and intervention of patient care although indwelling devices used widely in hospitals [24] and biofilm is known for colonizing these medical devices. In the present study, the maximum rate of biofilm positive isolates was identified from the blood (100%) and this finding was similar to another study which showed that 100% sterile fluids isolates were biofilm producers [22].
A catheter might have inserted for several purposes and this can be colonized. After blood samples, the ETT showed biofilm formation in 75% isolates and this could be explained by the fact that more specimens were obtained from patients admitted in ICU who were either intubated or needing ventilator support [24]. It was found that 66.67%, 30.43%, and 23.81% biofilm-producing isolates were from the drain, pus, and sputum respectively. This finding supports the fact that biofilm development is aided by tissue lesions, chronic respiratory disease, implanted medical devices, surgical wounds, etc. [9,25].

The antibiotic susceptibility of biofilm-producing bacteria is reduced because of a restricted antibiotic penetration, adaptive response and the occurrence of persisting cells [2]. In the present study, high resistance was noted among biofilm producers to an antipseudomonal cephalosporin (Ceftazidime and Cefepime), Piperacillin-tazobactam, Ciprofloxacin, and Gentamicin with 77%, 73%, 68%, and 59% respectively. These findings were nearly matching with other studies [21,22]. This may be due to the widespread use of these easily available antibiotics without knowing the infection status. All isolates were susceptible to polymyxin-B and colistin like other studies [1,2,21].

In the present study, resistance to Cefazidime, Cefepime, Piperacillin-tazobactam, Ciprofloxacin, Gentamicin, and Amikacin was comparatively higher in biofilm producer than a non-biofilm producer. The difference was statistically significant (p<0.05). It is similar to findings from other studies for most of the antibiotics tested [12,21,22]. So Meropenem, colistin, and polymyxin-B remain the treatment of choice for biofilm-producing isolates. However, due to their high toxicity, polymyxin is used for the treatment of only serious infections.

In the present study, it was found that there is an association between ESBL production and biofilm formation (Statistically significant, p=0.002). It was similar to another study [26] but the contrast study done by Dumaru et al. [12]. No statistically significant association could be established between MBL production and biofilm production (Statistically insignificant, p=0.19) which was in agreement with another study [20]. The resistance to antimicrobials in biofilm-producer may be explained by the fact like, there are an increased plasmid transfer and gene transfer among biofilm bacteria which further intensifies the problem of drug resistance [27] and also by the fact that in the process of biofilm development, drug resistance varies bacterium to bacterium [28].

**Conclusion**

The present study showed, 26.3% isolates of *P. aeruginosa* were biofilm producers and also showed that there is an association between biofilm formation and drug resistance. The present study emphasizes the relationship between ESBL production and biofilm formation in *P. aeruginosa*. Identification of biofilm-producing isolates is important because it leads to treatment failure due to the high drug resistance to multiple antibiotics. Biofilm may be controlled by replacing the device that was colonized and also by taking care of the device or wound that was already existing to prevent biofilm formation.

**Limitations-** The lack of confirmation of biofilm, ESBL, and MBL production by using molecular technologies are the drawbacks of this study.

**What does this study add to the existing knowledge?**

The present study highlight’s the importance of performing the test for biofilm production in *P. aeruginosa* isolates. By knowing the resistance pattern of these isolates’ clinicians can able to choose the right empirical antibiotic in life-threatening conditions.

**Author’s contribution**

**Dr. Kulkarni D.M.:** Data analysis, Manuscript writing
**Dr. Nilekar S.L.:** Study concept, data analysis
**Dr. Vidhya T:** Data collection, Manuscript writing

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical Approval:** This study was approved by the Institutional Ethics Committee

**References**

1. Haji SH. Detection of Biofilm Formation in Pseudomonas aeruginosa Isolates from Clinical Specimens. Zanco J Pure Appl Sci. 2018; 30[4]:83-89. doi: https://doi.org/10.21271/ZJPAS.30.4.9

2. Saha S, Devi KM, Damrolien S, Devi KS, . K, Sharma KT. Biofilm production and its correlation with antibiotic resistance pattern among clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital in north-east India. Int J Adv Med. 2018;5[4]:964. doi: http://dx.doi.org/10.18203/2349-3933.ijam20183129

3. Vallès J, Mariscal D, Cortés P, Coll P, Villagrá A, Diaz E, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: A 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med. 2004; 30[9]:1768-1775. doi: https://doi.org/10.1007/s00134-004-2382-6.

4. Haji SH, Kulkarni D.M, Nilekar S.L, Kulkarni D.M. Biofilm Production and its Correlation with Antibiotic Resistance Pattern Among Clinical Isolates of Pseudomonas aeruginosa. Int J Adv Med. 2018;5(4):964. doi: http://dx.doi.org/10.18203/2349-3933.ijam20183129
4. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001; 32[s2]:S146–S155. doi: https://doi.org/10.1086/320186.

5. Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Vol. 9, Trends in Microbiology. 2001. p. 50-52. doi: https://doi.org/10.1016/s0966-842x(00)01918-1 [PMID:11173226]

6. Sharma D, Misba L, Khan AU. Antibiotics versus biofilm: An emerging battleground in microbial communities. Antimicrob Resist Infect Control. 2019;8[1]:1–10. doi: https://doi.org/10.1186/s13756-019-0533-3.

7. Gebreyohannes G, Nyerere A, Bii C, Sbhatu DB. Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms. Heliyon. 2019;5[8]:e02192. doi: https://doi.org/10.1016/j.heliyon.2019.e02192.

8. Heiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PO, et al. The clinical impact of bacterial biofilms. Int J Oral Sci. 2011;3[2]:55–65. doi: https://doi.org/10.4248/IJOS11026.

9. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Vol. 284, Science. 1999. p. 1318–1322. doi: https://doi.org/10.1126/science.284.5418.1318.

10. Ali, Syed Sajeeed and Wakte PS. Isolation and identification of biofilm forming pseudomonas aeruginosa pseudomonas aeruginosa from wounds infection. Int J Curr Res. 2016;8[09]:38974–7.

11. Bose S, Khodke M. Detection Of Biofilm Producing Staphylococcii Need Of The Hour. J Clin Diagnostic Res. 2009;[3]:1915-1920.

12. Dumaru R, Baral R, Shrestha LB. Study of biofilm formation and antibiotic resistance pattern of gram-negative Bacilli among the clinical isolates at BPK IHS, Dharan. BMC Res Notes. 2019;12[1]:1–6. doi: https://doi.org/10.1186/s13104-019-4084-8.

13. Patricia M.Tille. Traditional cultivation and identification. In: Baily and Scott’s Diagnostic microbiology. 14th ed. Canada: Elsevier; 2017. p. 86–112.

14. Wayne P. CLSI,Performance Standards for Antimicrobial Susceptibility Testing. In: CLSI Supplement M100. 28th ed. 2018.

15. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2002 Oct;40[10]:3798–801. doi: https://doi.org/10.1128/jcm.40.10.3798-3801.2002.

16. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: A quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol. 1985;22[6]:996–1006.PMID: 3905855

17. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options. Vol. 25, Pharmacotherapy. 2005. p. 1353–64. doi: https://doi.org/10.1592/phco.2005.25.10.1353.

18. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob Agents Chemother. 2006 Jan;50[1]:43–8. doi: https://doi.org/10.1128/AAC.50.1.43-48.2006.

19. Heydari S and Eftekhar F. Biofilm Formation and β-Lactamase Production in Burn Isolates of Pseudomonas aeruginosa. Jundishapur J Microbiol . 2015;8[3]:e15514. doi: https://doi.org/10.5812/jjm.15514.

20. Baniya B, Pant ND, Neupane S, Khatiwada S, Yadav UN, Bhandari N, et al. Biofilm and metallo beta-lactamase production among the strains of Pseudomonas aeruginosa and Acinetobacter spp. at a tertiary care hospital in Kathmandu, Nepal. Ann Clin Microbiol Antimicrob. 2017;16[1]:6–9. doi: https://doi.org/10.1186/s12941-017-0245-6.

21. Shrestha R, Nayak N, Bhatta DR, Hamal D, Subramanya SH, Gokhale S. Drug Resistance and Biofilm Production among Pseudomonas aeruginosa Clinical Isolates in a Tertiary Care Hospital of Nepal. Nepal Med Coll J. 2019;21[2]:110-116. doi: https://doi.org/10.3126/nmcj.v21i2.25109

22. Gurung J, Khiyriem AB, Banik A, Lyngdoh WV, Choudhury B, Bhattacharyya P. Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian J Crit Care Med.
23. Rewatkar AR. Staphylococcus aureus and Pseudomonas aeruginosa- Biofilm formation Methods. IOSR J Pharm Biol Sci. 2013;8[5]:36–40.

24. Revdiwala S, Rajdev BM, Mulla S. Characterization of bacterial etiologic agents of biofilm formation in medical devices in critical care setup. Crit Care Res Pract. 2012;2012:1–6. doi: https://doi.org/10.1155/2012/945805.

25. Basak S, N. M, O. R, Kumar Mallick S. Biofilms: A Challenge to Medical Fraternity in Infection Control. In: Infection Control. Available at- https://doi.org/; 2013.

26. Nepal et al. Is there correlation of biofilm formation with multidrug resistance and ESBL production in pseudomonas aeruginosa? Eur J Biomed Pharm Sci. 2017;4[01]:366–72. Available at-http://www.ejbps.com

27. Angel Díaz M, Ramón Hernández J, Martínez-Martínez L, Rodríguez-Baño J, Pascual A. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study [GEIH-BLEE project, 2006]. Enferm Infecc Microbiol Clin. 2003;21[2]:503-510. doi: https://doi.org/10.1016/j.eimc.2008.09.006.

28. Singh S, Singh SK, Chowdhury I, Singh R. Understanding the Mechanism of Bacterial Biofilms Resistance to Antimicrobial Agents. Open Microbiol J. 2017;11[1]:53–62. doi: https://doi.org/10.2174/1874285801711010053.

How to cite this article?

Kulkarni D.M, Nilekar S.L., Vidhya T. Association of biofilm production in ESBL and MBL producing clinical isolates of Pseudomonas aeruginosa. Trop J Path Micro 2020;6(2):175-181. doi:10.17511/jopm.2020.i02.10